S&P Global Ratings has revised its outlook on McKesson Corp (NYSE:MCK). to positive from stable, while affirming its 'BBB+' ...

Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors ...

McKesson MCK delivered an 18% increase in revenues ($95.3 billion) and a 16% rise in adjusted operating profit during the ...

Under the deal, J&J would be in line for a $5 billion payment over nine years, while wholesalers McKesson, Cardinal Health and AmerisourceBergen would share responsibility for the remaining $21 ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Investors should watch how McKesson navigates competitive and regulatory pressure. Notable competitors like Cardinal Health could challenge McKesson's market position. Upcoming quarters may see ...

Its two close competitors are Cencora and McKesson. Together, the three operate as a pharmaceutical wholesale and distribution oligopoly, supplying over 90% of the US market. Narrow-moat Cardinal ...

and Cardinal Health. According to TipRanks, Anderson CFA has an average return of -7.4% and a 37.38% success rate on recommended stocks. Currently, the analyst consensus on McKesson is a Strong ...

In a report released yesterday, Elizabeth Anderson CFA from Evercore ISI maintained a Buy rating on McKesson (MCK – Research Report), with a ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.